Safety and Efficacy of Medicinal Cannabis in the Treatment of Fibromyalgia: A Systematic Review
Authors:
- 1 March 2021
- journal article
- review article
- Published by SAGE Publications in The Journal of Alternative and Complementary Medicine
- Vol. 27 (3) , 198-213
Abstract
Background: Fibromyalgia (FMS) is a complex condition that is characterized by various pain syndromes and fatigue, among other symptoms experienced. Current medical treatment of FMS involves both pharmacological and nonpharmacological approaches, but often with ineffective outcomes. Medicinal cannabis has the potential to be a therapeutic option for patients with FMS due to the positive research in chronic pain management. In addition, it has been found to have fewer adverse effects compared with currently available pain medications. This literature review aims at answering whether medicinal cannabis is reported to be safe and effective for the treatment of pain and symptomology experienced by people with FMS. Methods: A systematic review was conducted on human trials utilizing cannabis in FMS. MEDLINE, Embase, CINAHL, AMED, Scopus, and Cochrane CENTRAL were used for databases search, and mesh terms were used for cannabis and FMS. The search was limited to studies conducted from 2000 to 2020. Results: From the 181 citations identified, 10 studies were included after title, abstract, and full text screening occurred. A total of 1136 of patients (intervention n = 945, control n = 108, crossover n = 83) participated in the 10 studies ranging from 9 to 383 patients (mean = 114, median = 36). Of these studies, there were three randomized controlled trials, six observational studies, and one study that compared the management of chronic pain patients with FMS patients. Cannabis was found to be safe and well tolerated in FMS. The main adverse events identified included feeling “high,” dizziness/vertigo, dry mouth, cough, red eyes, and drowsiness with no serious adverse events reported. Conclusions: This literature review identified that medical cannabis may be beneficial for some people with FMS. Further studies are required to confirm its efficacy, what type of cannabis is the most effective form to use, and what assessment tools need to be utilized to understand how to quantify clinical outcomes.Keywords
This publication has 55 references indexed in Scilit:
- Health-resource use and costs associated with fibromyalgia in France, Germany, and the United StatesClinicoEconomics and Outcomes Research, 2013
- Abnormal endogenous pain modulation is a shared characteristic of many chronic pain conditionsExpert Review of Neurotherapeutics, 2012
- Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effectsBritish Journal of Pharmacology, 2011
- The Effects of Nabilone on Sleep in Fibromyalgia: Results of a Randomized Controlled TrialAnesthesia & Analgesia, 2010
- Adverse effects of medical cannabinoids: a systematic reviewCanadian Medical Association Journal, 2008
- Disability and quality of life in patients with fibromyalgiaHealth and Quality of Life Outcomes, 2008
- Mechanisms of Disease: genetics of fibromyalgiaNature Clinical Practice Rheumatology, 2006
- The Endocannabinoid System as an Emerging Target of PharmacotherapyPharmacological Reviews, 2006
- Delta‐9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain reliefCurrent Medical Research and Opinion, 2006
- Fear-avoidance and its consequences in chronic musculoskeletal pain: a state of the artPain, 2000